30 results
8-K
CELU
Celularity Inc - Ordinary Shares
21 May 24
Results of Operations and Financial Condition
9:25am
presentation to provide updates and summaries of its business (the “Investor and R&D Day Presentation”). Celularity is posting a copy of the Investor and R&D Day … Presentation to the “Investor Relations” portion of its website at https://celularity.com/investor-relations/.
A copy of the Investor and R&D Day
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
16 May 22
Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:47pm
& Development (R&D) Expenses: R&D expenses were $21.7 million for the first quarter of 2022, compared to $17.0 million for the first quarter of 2021
8-K/A
EX-99.4
CELU
Celularity Inc - Ordinary Shares
16 Aug 21
Completion of Acquisition or Disposition of Assets
5:23pm
and development (“R&D”) tax credits. Other expense, net for the three months ended June 30, 2020 included $3.8 million in net proceeds from the sale of unused New … Jersey NOLs and unused R&D tax credits.
Comparison of Six Months Ended June 30, 2021 to June 30, 2020
Six Months Ended
Percent
June 30,
June 30
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
31 Mar 22
Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
4:06pm
, as well as new distribution agreements.
Research & Development (R&D) Expenses: R&D expenses were $24.7 million for the fourth quarter of 2021 and $88.4
8-K/A
EX-99.3
CELU
Celularity Inc - Ordinary Shares
16 Aug 21
Completion of Acquisition or Disposition of Assets
5:23pm
Changes in assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other assets
Sale of NOL and R&D tax credits
Accounts payable … ”) and unused research and development (“R&D”) tax credits through the New Jersey Economic Development Authority’s Technology Business Tax Certificate
424B3
jzix014r0tgxs7uya
12 Nov 21
Prospectus supplement
4:45pm
8-K
EX-99.3
wzw9i
8 Jan 21
Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
7:03am
425
EX-99.3
8pur7r
8 Jan 21
Business combination disclosure
7:02am
425
67799nd8 zjt
11 Feb 21
Business combination disclosure
6:27am
425
bkxgapiuw a3
27 Apr 21
Business combination disclosure
8:40pm
424B3
70j3c8f
10 Aug 22
Prospectus supplement
12:00am
424B3
zo2nida 4gbouw9zii
10 Aug 22
Prospectus supplement
12:00am